Replies to post #3527 on Adamis Pharmaceuticals Corp (ADMP)

[Headsupmonk]

I concur 66.

[ShortsRClowns]

'Risk of Accidental Needlestick Injury: After use, the ZIMHI needle is exposed until the safety guard is deployed. Stress to patients the importance of familiarizing themselves with the device and its operation prior to experiencing an emergency situation, and to immediately seek medical attention should a needlestick occur.'

Since the word on the street is that non professionals won't have access to this device I guess all is a moot point and we don't have to worry about everyday folks not following instructions. So many scenarios avoided.

Thank you, I enjoyed your response so much. Exactly what I was looking for.

[ShortsRClowns]

Oh, I forgot one thing. Assuming Zimhi had a needle, which I'm told it doesn't, but putting that aside, why mess with a needle when the nasal applicators have been highly effective and have ZERO risk of a prick? Add to that research that says it's more about timing of getting the treatment than applicator in order to treat the 'victim'.

Facts don't matter anymore, I get it. Lets also ignore trying to gain market share and the many challenges that brings with it. Up against existing products which are very effective with zero risk to the individuals administering it and the public (aka spreading of diseases). Markets have spoken, post FDA approval, on how they feel about it.

I've really enjoyed this, probably too much. Go Tempol, all or nothing!